Chemistry:CB-13
From HandWiki
Short description: Chemical compound
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C26H24O2 |
| Molar mass | 368.476 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
CB-13 (CRA13, SAB-378)[1] is a cannabinoid drug, which acts as a potent agonist at both the CB1 and CB2 receptors, but has poor blood–brain barrier penetration, and so produces only peripheral effects at low doses, with symptoms of central effects such as catalepsy only appearing at much higher dose ranges. It has antihyperalgesic properties in animal studies,[2] and has progressed to preliminary human trials.[3]
Legal Status
As of October 2015 CB-13 is a controlled substance in China.[4]
CB-13 is a Schedule I controlled substance in North Dakota.[5]
See also
References
- ↑ "Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a peripherally restricted cannabinoid CB1/CB2 receptor agonist, inhibits gastrointestinal motility but has no effect on experimental colitis in mice". The Journal of Pharmacology and Experimental Therapeutics 334 (3): 973–980. September 2010. doi:10.1124/jpet.110.169946. PMID 20571060.
- ↑ "Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration". Journal of Medicinal Chemistry 50 (16): 3851–3856. August 2007. doi:10.1021/jm070317a. PMID 17630726.
- ↑ "Cannabinoid receptor agonist 13, a novel cannabinoid agonist: first in human pharmacokinetics and safety". Drug Metabolism and Disposition 37 (4): 827–833. April 2009. doi:10.1124/dmd.108.024000. PMID 19144772.
- ↑ "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in zh). China Food and Drug Administration. 27 September 2015. http://www.sfda.gov.cn/WS01/CL0056/130753.html.
- ↑ "Schedule 1". Sixty-eighth Legislative Assembly of North Dakota. 3 January 2023. https://www.ndlegis.gov/prod/assembly/68-2023/regular/documents/23-8099-04000.pdf.
 |  |
